Processa Pharmaceuticals, Inc.: 10-Q filed 2023-11-13

Name: Processa Pharmaceuticals, Inc.: 10-Q filed 2023-11-13
Creator: Processa Pharmaceuticals, Inc.

What Processa Pharmaceuticals, Inc. reported in its quarterly report filed 2023-11-13 (fiscal Q3 2023): 32 published measures, 83 facts as tagged in accession 0001493152-23-040472.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-11-13
Fiscal period: fiscal Q3 2023
Accession: 0001493152-23-040472 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Processa Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-09-30	8,082,726	USD
At 2022-12-31	8,619,851	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-09-30	914,847	USD
At 2022-12-31	1,149,110	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-09-30	7,167,879	USD
At 2023-06-30	9,159,682	USD
At 2023-03-31	10,142,249	USD
At 2022-12-31	7,470,741	USD
At 2022-09-30	17,240,025	USD
At 2022-06-30	20,081,867	USD
At 2022-03-31	23,236,866	USD
At 2021-12-31	25,485,100	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2023-09-30	6,860,672	USD
At 2022-12-31	6,503,595	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-2,081,951	USD	92
2023-01-01 to 2023-09-30	-8,716,589	USD	273
2023-04-01 to 2023-06-30	-2,612,565	USD	91
2023-01-01 to 2023-03-31	-4,022,073	USD	90
2022-07-01 to 2022-09-30	-6,020,410	USD	92
2022-01-01 to 2022-09-30	-14,411,909	USD	273
2022-04-01 to 2022-06-30	-5,164,368	USD	91
2022-01-01 to 2022-03-31	-3,227,131	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-5,939,478	USD	273
2022-01-01 to 2022-09-30	-7,107,758	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	2,776	USD	273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	0	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	6,299,331	USD	273
2022-01-01 to 2022-09-30	-335,247	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-2,776	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-09-30	-72,964,150	USD
At 2022-12-31	-64,247,561	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	27,002,908	shares	92
2023-01-01 to 2023-09-30	25,585,222	shares	273
2022-07-01 to 2022-09-30	16,200,222	shares	92
2022-01-01 to 2022-09-30	15,991,653	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	27,002,908	shares	92
2023-01-01 to 2023-09-30	25,585,222	shares	273
2022-07-01 to 2022-09-30	16,200,222	shares	92
2022-01-01 to 2022-09-30	15,991,653	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-0.08	USD/shares	92
2023-01-01 to 2023-09-30	-0.34	USD/shares	273
2022-07-01 to 2022-09-30	-0.37	USD/shares	92
2022-01-01 to 2022-09-30	-0.9	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-0.08	USD/shares	92
2023-01-01 to 2023-09-30	-0.34	USD/shares	273
2022-07-01 to 2022-09-30	-0.37	USD/shares	92
2022-01-01 to 2022-09-30	-0.9	USD/shares	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2023-09-30	2,694	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	142,894	USD	92
2023-01-01 to 2023-09-30	803,521	USD	273
2022-07-01 to 2022-09-30	3,213,815	USD	92
2022-01-01 to 2022-09-30	6,052,081	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-2,167,612	USD	92
2023-01-01 to 2023-09-30	-8,987,611	USD	273
2022-07-01 to 2022-09-30	-6,057,118	USD	92
2022-01-01 to 2022-09-30	-14,457,581	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-09-30	7,907,462	USD
At 2022-12-31	8,386,729	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-09-30	826,070	USD
At 2022-12-31	998,556	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2023-09-30	346,299	USD
At 2022-12-31	327,548	USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-09-30	24,631,474	shares
At 2022-12-31	16,035,400	shares

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2023-09-30	167,035	USD
At 2022-12-31	227,587	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2023-09-30	171,521	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2023-09-30	172,570	USD
At 2022-12-31	233,122	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2023-09-30	202,236	USD
At 2022-12-31	403,061	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2023-09-30	1,046,790	USD
At 2022-12-31	1,883,134	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	1,015,872	USD	92
2023-01-01 to 2023-09-30	4,508,818	USD	273
2022-07-01 to 2022-09-30	2,920,280	USD	92
2022-01-01 to 2022-09-30	6,137,674	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	82	USD	273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	591,372	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	6,352,077	USD	273
2022-01-01 to 2022-09-30	-35,247	USD	273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	18,751	USD	273
2022-01-01 to 2022-09-30	92,161	USD	273

Inspect the source

Entity: Processa Pharmaceuticals, Inc. / CIK 0001533743
Captured: 2026-09-20T09:16:31.348Z
SEC response SHA-256: 5f3216d9024f2a7fc94b315f5bf243c7efb048273a6be394a2f74186d7af2a31

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001533743.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))